162 related articles for article (PubMed ID: 37389827)
1. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma.
Nikkarinen A; Lokhande L; Amini RM; Jerkeman M; Porwit A; Molin D; Enblad G; Kolstad A; Räty R; Hutchings M; Weibull CE; Hollander P; Ek S; Glimelius I
Blood Adv; 2023 Sep; 7(18):5304-5313. PubMed ID: 37389827
[TBL] [Abstract][Full Text] [Related]
2. Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages.
Koh YW; Shin SJ; Park C; Yoon DH; Suh C; Huh J
Hematol Oncol; 2014 Dec; 32(4):178-86. PubMed ID: 24910369
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
4. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
5. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
Papin A; Tessoulin B; Bellanger C; Moreau A; Le Bris Y; Maisonneuve H; Moreau P; Touzeau C; Amiot M; Pellat-Deceunynck C; Le Gouill S; Chiron D
Leukemia; 2019 Oct; 33(10):2442-2453. PubMed ID: 30940906
[TBL] [Abstract][Full Text] [Related]
6. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
[TBL] [Abstract][Full Text] [Related]
7. Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy.
Koudouna A; Gkioka AI; Gkiokas A; Tryfou TM; Papadatou M; Alexandropoulos A; Bartzi V; Kafasi N; Kyrtsonis MC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474108
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma.
Lauridsen KM; Hokland M; Al-Karradi S; Møller HJ; Donskov F; Andersen MN
Cancer Immunol Immunother; 2023 Feb; 72(2):461-473. PubMed ID: 35953682
[TBL] [Abstract][Full Text] [Related]
9. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P; Nikkarinen A; Ek S; Glimelius I
Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
[TBL] [Abstract][Full Text] [Related]
10. Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.
Rodrigues JM; Nikkarinen A; Hollander P; Weibull CE; Räty R; Kolstad A; Amini RM; Porwit A; Jerkeman M; Ek S; Glimelius I
Br J Haematol; 2021 May; 193(3):520-531. PubMed ID: 33686666
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.
Li YL; Shi ZH; Wang X; Gu KS; Zhai ZM
BMC Cancer; 2019 Nov; 19(1):1049. PubMed ID: 31694577
[TBL] [Abstract][Full Text] [Related]
12. High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis.
Li P; Yuan J; Ahmed FS; McHenry A; Fu K; Yu G; Cheng H; Xu ML; Rimm DL; Pan Z
Front Oncol; 2021; 11():701492. PubMed ID: 34527580
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
[TBL] [Abstract][Full Text] [Related]
14. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
16. CD163 as a Biomarker in Colorectal Cancer: The Expression on Circulating Monocytes and Tumor-Associated Macrophages, and the Soluble Form in the Blood.
Krijgsman D; De Vries NL; Andersen MN; Skovbo A; Tollenaar RAEM; Møller HJ; Hokland M; Kuppen PJK
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824692
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
[TBL] [Abstract][Full Text] [Related]
19. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML
Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709
[TBL] [Abstract][Full Text] [Related]
20. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.
Jensen TO; Schmidt H; Møller HJ; Høyer M; Maniecki MB; Sjoegren P; Christensen IJ; Steiniche T
J Clin Oncol; 2009 Jul; 27(20):3330-7. PubMed ID: 19528371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
